<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911226-0042</DOCNO><DOCID>911226-0042.</DOCID><HL>   Technology Brief -- Synergen Inc.:   University Foundation, Firm   Share Patent on a Protein</HL><DATE>12/26/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B4</SO><CO>   SYGN</CO><MS>TECHNOLOGY (TEC)</MS><IN>BIOTECHNOLOGY (BTC)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><NS>PATENTS (PAT)</NS><RE>COLORADO (CO)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   Synergen Inc., Boulder, Colo., said it received a patentwith the University of Colorado Foundation Inc. on the DNAfor interleukin-1 inhibitors and methods for producinginterleukin-1 inhibitors.   The pharmaceutical concern is testing its drug Antril, aninterleukin-1 receptor antagonist, or inhibitor, on severaldiseases and disorders-including sepsis syndrome, rheumatoidarthritis, asthma and inflammatory bowel disease-related toinflammation caused by an overproduction of interleukin-1.The company said the patent covers 31 claims for productionof interleukin-1 inhibitors, DNA, plasmids, vectors and hostcells useful in producing the protein.</LP><TEXT>   University of Colorado scientists collaborated in thediscovery of the protein.   A Synergen spokeswoman said that the company also hasother patents pending on the protein.</TEXT></DOC>